Prognostic value of high-sensitivity C-reactive protein in patients undergoing percutaneous coronary intervention with different glycemic metabolism status
An erratum to this article was published (Cardiovasc Diabetol, 6 Dec 2024 ↗)
Authors' conclusion
Elevated hsCRP is an independent risk factors of MACEs in patients undergoing PCI irrespective of glycemic metabolism status.
Study context
- Population
- Consecutive patients undergoing percutaneous coronary intervention (PCI) for coronary artery stenosis, with or without diabetes mellitus (DM)
- Participants
- 8,050 patients
- Exposure
- High High-sensitivity C-reaction protein (hsCRP) vs low hsCRP, with or without DM
- Outcome
- MACE: all-cause mortality, MI, stroke and unplanned vessel revascularization
- Follow-up
- 3 year
Methodological detailslarge-scale, consecutive patients
- Large-scale
- Consecutive patients
Main finding
As reported in the abstract
MACE:
- All-cause mortality
- MI
- Stroke
- Unplanned vessel revascularization
- Patients with MACE
- 674
- Highest incidence of MACE in hsCRP-H/DM (Kaplan-Meier)
- P < 0.001
Observational data: associations, not effects.
Further findings
hsCRP and MACE (restricted cubic spline)
- Positive linear relationship between hsCRP and MACE
Parts of this Brief are withheld: the automatic checks could not confirm them against the abstract.
Original publication
Prognostic value of high-sensitivity C-reactive protein in patients undergoing percutaneous coronary intervention with different glycemic metabolism status. Cardiovasc Diabetol. Published 24 August 2023. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →